Antifungal Prophylaxis in Solid Organ Transplant Recipients
Solid organ transplantation (SOT) is a treatment method that improves quality of life and survival of patients with end-stage organ failure. Immunosuppressive treatments given to these patients may predispose to the development of invasive fungal infections (IFI). The incidence of IFI in SOT recipients, which is between 5% and 42%, depends on the organ to be transplanted. Although Candida spp., followed by Aspergillus spp. are the most common microorganisms, among fungal pathogens, this situation varies according to transplant type. The mortality rate associated with these IFI can be high. Therefore, antifungal prophylaxis may be necessary for SOT recipients. Many transplantation centers employ antifungal strategies according to their own experience because of the lack of randomized controlled studies. If the antifungal prophylaxis is given to all patients, antimicrobial resistance and drug-drug interactions may occur. Therefore, it is important to identify patients at a high risk of developing IFI. In this paper, epidemiology, risk factors, literature data and antifungal prophylaxis associated with IFI in liver, kidney, small intestine, pancreas, heart, and lung transplant recipients are reviewed..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2015 |
|---|---|
| Erschienen: |
2015 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:4 |
|---|---|
| Enthalten in: |
Mediterranean Journal of Infection, Microbes and Antimicrobials - 4(2015) |
| Sprache: |
Türkisch |
|---|
| Beteiligte Personen: |
Şebnem ŞENOL [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
Amphotericin B |
|---|
| doi: |
10.4274/mjima.2015.7 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ002421860 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ002421860 | ||
| 003 | DE-627 | ||
| 005 | 20230310190306.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230225s2015 xx |||||o 00| ||tur c | ||
| 024 | 7 | |a 10.4274/mjima.2015.7 |2 doi | |
| 035 | |a (DE-627)DOAJ002421860 | ||
| 035 | |a (DE-599)DOAJf74b70c16bf547c89795c55c9a1c73be | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a tur | ||
| 050 | 0 | |a RC109-216 | |
| 100 | 0 | |a Şebnem ŞENOL |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Antifungal Prophylaxis in Solid Organ Transplant Recipients |
| 264 | 1 | |c 2015 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Solid organ transplantation (SOT) is a treatment method that improves quality of life and survival of patients with end-stage organ failure. Immunosuppressive treatments given to these patients may predispose to the development of invasive fungal infections (IFI). The incidence of IFI in SOT recipients, which is between 5% and 42%, depends on the organ to be transplanted. Although Candida spp., followed by Aspergillus spp. are the most common microorganisms, among fungal pathogens, this situation varies according to transplant type. The mortality rate associated with these IFI can be high. Therefore, antifungal prophylaxis may be necessary for SOT recipients. Many transplantation centers employ antifungal strategies according to their own experience because of the lack of randomized controlled studies. If the antifungal prophylaxis is given to all patients, antimicrobial resistance and drug-drug interactions may occur. Therefore, it is important to identify patients at a high risk of developing IFI. In this paper, epidemiology, risk factors, literature data and antifungal prophylaxis associated with IFI in liver, kidney, small intestine, pancreas, heart, and lung transplant recipients are reviewed. | ||
| 650 | 4 | |a Solid organ transplantation | |
| 650 | 4 | |a antifungal prophylaxis | |
| 650 | 4 | |a invasive fungal infection | |
| 650 | 4 | |a posaconasole | |
| 650 | 4 | |a amphotericin B | |
| 653 | 0 | |a Medicine | |
| 653 | 0 | |a R | |
| 653 | 0 | |a Infectious and parasitic diseases | |
| 700 | 0 | |a Oya Eren KUTSOYLU |e verfasserin |4 aut | |
| 700 | 0 | |a Onur KAYA |e verfasserin |4 aut | |
| 700 | 0 | |a Meltem AVCI |e verfasserin |4 aut | |
| 700 | 0 | |a Meltem IŞIKGÖZ TAŞBAKAN |e verfasserin |4 aut | |
| 700 | 0 | |a Vildan AVKAN OĞUZ |e verfasserin |4 aut | |
| 700 | 0 | |a Betil Özhak BAYSAN |e verfasserin |4 aut | |
| 700 | 0 | |a Sema Alp ÇAVUŞ |e verfasserin |4 aut | |
| 700 | 0 | |a Çiğdem Banu ÇETİN |e verfasserin |4 aut | |
| 700 | 0 | |a Çağrı ERGİN |e verfasserin |4 aut | |
| 700 | 0 | |a Bülent ERTUĞRUL |e verfasserin |4 aut | |
| 700 | 0 | |a Selda SAYIN KUTLU |e verfasserin |4 aut | |
| 700 | 0 | |a Murat KUTLU |e verfasserin |4 aut | |
| 700 | 0 | |a Gülşen MERMUT |e verfasserin |4 aut | |
| 700 | 0 | |a Dilek Yeşim METİN |e verfasserin |4 aut | |
| 700 | 0 | |a Barçın ÖZTÜRK |e verfasserin |4 aut | |
| 700 | 0 | |a Hüsnü PULLUKÇU |e verfasserin |4 aut | |
| 700 | 0 | |a Özge TURHAN |e verfasserin |4 aut | |
| 700 | 0 | |a Nur YAPAR |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Mediterranean Journal of Infection, Microbes and Antimicrobials |d Galenos Yayinevi, 2017 |g 4(2015) |w (DE-627)DOAJ000019046 |x 2147673X |7 nnns |
| 773 | 1 | 8 | |g volume:4 |g year:2015 |
| 856 | 4 | 0 | |u https://doi.org/10.4274/mjima.2015.7 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/f74b70c16bf547c89795c55c9a1c73be |z kostenfrei |
| 856 | 4 | 0 | |u http://www.mjima.org/pdf.php?&id=57 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2147-673X |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 4 |j 2015 | ||